Market Overview - The Shanghai Composite Index rose by 0.14% on January 22, with 22 out of the 28 sectors in the Shenwan classification experiencing gains, led by the construction materials and defense industries, which increased by 4.09% and 3.23% respectively [1] - The beauty and banking sectors saw the largest declines, with decreases of 0.76% and 0.43% respectively [1] Capital Flow Analysis - The main capital outflow from the two markets totaled 21.612 billion yuan, with 12 sectors experiencing net inflows [1] - The telecommunications sector had the highest net inflow, amounting to 8.019 billion yuan, and it rose by 2.83% [1] - The defense industry also saw significant inflow, with a net inflow of 5.713 billion yuan and a daily increase of 3.23% [1] - The electronics sector faced the largest net outflow, totaling 13.206 billion yuan, followed by the power equipment sector with an outflow of 7.206 billion yuan [1] Pharmaceutical and Biological Industry Performance - The pharmaceutical and biological sector declined by 0.42%, with a net capital outflow of 3.027 billion yuan [2] - Out of 478 stocks in this sector, 253 rose while 204 fell, with 2 stocks hitting the daily limit up [2] - The top three stocks with the highest net inflow were Sanbo Brain Science (1.42 billion yuan), Yunnan Baiyao (667.561 million yuan), and Innovation Medical (637.008 million yuan) [2] - The sector's outflow was led by Hengrui Medicine, which saw a net outflow of 372.7538 million yuan, followed by Xingqi Eye Medicine and Aidi Pharmaceutical with outflows of 208.3529 million yuan and 121.6946 million yuan respectively [3]

Market Overview - The medical services sector increased by 0.18% on January 21, with Nanmo Biology leading the gains [1] - The Shanghai Composite Index closed at 4116.94, up 0.08%, while the Shenzhen Component Index closed at 14255.12, up 0.7% [1] Top Gainers in Medical Services - Nanmo Biology (688265) closed at 49.79, up 7.01% with a trading volume of 20,000 shares and a transaction value of 98.02 million [1] - Hite Biology (300683) closed at 29.67, up 5.74% with a trading volume of 107,800 shares and a transaction value of 32.2 million [1] - Dean Diagnostics (300244) closed at 26.46, up 5.59% with a trading volume of 796,300 shares and a transaction value of 2.13 billion [1] - ST Zhongzhu (600568) closed at 2.64, up 5.18% with a trading volume of 376,500 shares and a transaction value of 9.81 million [1] - Tongce Medical (600763) closed at 46.51, up 4.99% with a trading volume of 198,600 shares and a transaction value of 911 million [1] Top Losers in Medical Services - Digital Human (920670) closed at 18.72, down 4.44% with a trading volume of 74,500 shares and a transaction value of 143 million [2] - Hongbo Pharmaceutical (301230) closed at 46.36, down 1.88% with a trading volume of 131,200 shares and a transaction value of 614 million [2] - Chengda Pharmaceutical (301201) closed at 41.39, down 1.76% with a trading volume of 36,600 shares and a transaction value of 153 million [2] Capital Flow in Medical Services - The medical services sector saw a net inflow of 50.51 million from institutional investors, while retail investors experienced a net outflow of 375 million [2] - The sector's overall capital flow indicates a strong interest from institutional and speculative investors, with retail investors pulling back [2][3] Notable Capital Inflows - Sanbo Brain Science (301293) had a net inflow of 91.48 million, representing 9.03% of its total capital [3] - Tongce Medical (600763) saw a net inflow of 83.46 million, accounting for 9.16% of its total capital [3] - BGI Genomics (300676) recorded a net inflow of 51.81 million, which is 8.37% of its total capital [3]

（文章来源：证券日报） 证券日报网讯 1月20日，三博脑科发布公告称，公司第三届董事会第十六次会议、2026年第一次临时股 东会审议通过了《关于部分募投项目结项并将节余募集资金永久补充流动资金及注销募集资金专户的议 案》。同意将"首都医科大学三博脑科医院建设项目"结项，同意注销募集资金专户，并将截至2025年12 月22日的节余募集资金7，027.72万元（含扣除手续费后的利息收入、现金管理收益等，实际金额以资 金转出当日募集资金专户余额为准）永久补充流动资金，用于公司日常生产经营及业务发展。公司于近 日办理完成了上述相关募集资金专用账户的注销手续，最终实际永久补充流动资金的节余募集资金金额 为7，029.71万元。本次涉及募集资金专户注销后，公司及北京三博脑科医院有限公司与保荐机构、监 管银行签订的募集资金四方监管协议随之终止。 ...

证券代码：301293 证券简称：三博脑科 公告编号：2026-004 三博脑科医院管理集团股份有限公司 关于注销部分募集资金专户的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、募集资金基本情况 经中国证券监督管理委员会证监许可〔2023〕534 号文《关于同意三博脑科 医院管理集团股份有限公司首次公开发行股票注册的批复》同意注册，并经深圳 证券交易所同意，三博脑科医院管理集团股份有限公司（以下简称"公司"）首次 公开发行人民币普通股（A 股）39,612,900 股，每股面值人民币 1.00 元，发行价 格为 29.60 元/股。本次发行募集资金总额 117,254.1840 万元；扣除发行费用（不 含增值税）后，募集资金净额为 106,163.91 万元，募集资金已于 2023 年 4 月 27 日划至公司指定账户，立信会计师事务所（特殊普通合伙）对公司本次公开发行 新股的资金到位情况进行了审验，并于2023年4月27日出具了"信会师报字[2023] 第 ZB10925 号"《验资报告》。公司已对募集资金采取了专户存储，并与专户银 行、保荐机构 ...

Group 1 - The core point of the article is that Sanbo Brain Science (301293.SZ) has confirmed that, apart from a previously completed intervention brain-computer interface surgery at its Fujian branch, there are no other surgeries currently being conducted within the group [1] Group 2 - The company has engaged with investors through an interactive platform to provide updates on its surgical activities [1] - The mention of the completed surgery indicates ongoing developments in the field of brain-computer interface technology [1] - The lack of additional surgeries may suggest a focus on consolidating existing operations before expanding further [1]

Core Viewpoint - Sanbo Neuroscience (301293.SZ) is a medical service group specializing in neurology, primarily providing advanced neurosurgical services [1] Group 1: Company Overview - The company operates a network of hospitals focused on comprehensive medical services with a strong emphasis on high-end neurosurgery [1] - Currently, the company does not engage in the research, production, or sales of brain-computer interface products [1] Group 2: Investment Activities - The company has previously invested in the Beinao Phase I Fund, which will primarily focus on new-generation medical devices, consumables, and pharmaceuticals for the diagnosis and treatment of neurological diseases [1]

北京市中伦律师事务所 关于三博脑科医院管理集团股份有限公司 2026 年第一次临时股东会的 法律意见 二〇二六年一月 北京 • 上海 • 深圳 • 广州 • 武汉 • 成都 • 重庆 • 青岛 • 杭州 • 南京 • 海口 • 东京 • 香港 • 伦敦 • 纽约 • 洛杉矶 • 旧金山 • 阿拉木图 Beijing • Shanghai • Shenzhen • Guangzhou • Wuhan • Chengdu • Chongqing • Qingdao • Hangzhou • Nanjing • Haikou • Tokyo • Hong Kong • London • New York • Los Angeles • San Francisco • Almaty 北京市中伦律师事务所 关于三博脑科医院管理集团股份有限公司 2026 年第一次临时股东会的 法律意见 致：三博脑科医院管理集团股份有限公司 北京市中伦律师事务所（以下简称"本所"）接受三博脑科医院管理集团股份 有限公司（以下简称"公司"）委托，指派本所律师列席公司 2026 年第一次临时 股东会（以下简称"本次股东会"），并出具本法律意见 ...

特别提示： 三博脑科医院管理集团股份有限公司 2026 年第一次临时股东会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 证券代码：301293 证券简称：三博脑科 公告编号：2026-003 1、本次股东会未出现否决议案的情形； 2、本次股东会未涉及变更以往股东会已通过的决议。 一、会议召开和出席情况 2、会议召开的合法、合规性：本次股东会的召开符合有关法律、行政法规、 部门规章、规范性文件及《公司章程》的规定。 3、会议召开时间： （1）现场会议时间：2026 年 1 月 16 日下午 15:30 （2）网络投票时间：通过深圳证券交易所交易系统进行网络投票的具体时 间为：2026 年 1 月 16 日上午 9:15-9:25、9:30-11:30，下午 13:00-15:00；通过深 圳证券交易所互联网投票系统投票的具体时间为：2026 年 1 月 16 日 9:15-15:00 期间的任意时间。 4、会议召开方式：现场投票与网络投票相结合的方式。 5、现场会议召开地点：北京市海淀区世纪金源香山商旅酒店 831 栋公司会 议室 （一）会议召开情况 ...

（文章来源：证券日报） 证券日报网讯 1月15日，三博脑科在互动平台回答投资者提问时表示，目前公司财务部门正在核算2025 年度的财务数据，如触及披露标准，公司将按规定在指定媒体公开披露，请留意公司的公告。 ...

Core Viewpoint - Sanbo Brain Science (301293.SZ) is making progress in its brain-computer interface (BCI) business, but its main revenue still comes from high-end neurosurgery services, with BCI technology currently contributing minimally to overall performance [2]. Group 1: Surgical Trials - The company has completed one interventional brain-computer interface surgery at its Fujian branch, with no other surgeries reported within the group [2]. Group 2: External Investment and Collaboration - Sanbo Brain Science has previously invested in three brain science funds and has established a joint research center for precision medicine in collaboration with Tsinghua University’s School of Biomedical Engineering [2]. - Ongoing projects related to these collaborations are still in progress [2]. Group 3: Revenue Impact - The revenue generated from the company's neuromodulation technology is currently very small, having a negligible impact on the company's overall performance [2].